They found that MITF silencing frequently led to downregulation of pro-oncogenic factors, as c-Myc, c-Myc target genes, IL1B, NT5E (CD73) and molecules related to tumor immune evasion, as well as to consistent upregulation of genes associated with immune activation and cell adhesion, thus suggesting a tumor-promoting role for MITF activity in basal breast cancer [31]. This evidence concerns the gene MYC and breast cancer.